Alpha Tau Medical Ltd. (DRTS) 10-Year Financial Performance & Capital Metrics

DRTS • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

AboutAlpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.Show more

Revenue $0
EBITDA -$35M -195.1%
Net Income -$32M -8.9%
EPS (Diluted) -0.45 -7.1%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -43.16% -40.7%
ROIC -36.88% -231.0%
Debt/Equity 0.20 +27.3%
Interest Coverage -104.77 -111.5%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 95 (top 5%)

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-34.85%

EPS CAGR

10Y-

5Y-

3Y-

TTM-23.51%

ROCE

10Y Avg-21.63%

5Y Avg-20.65%

3Y Avg-16.45%

Latest-40.54%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.45	53.21	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	11.82B	44.08	25.05	18.49%	29.63%	31.37%	5.36%	0.09
INBXInhibrx Biosciences, Inc.	1.07B	73.28	0.63	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.24B	6.55	-3.10		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.38B	7.94	-3.36	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	987.53M	10.14	-5.54			-33.24%		0.01
ZLABZai Lab Limited	2.07B	18.72	-7.20	49.59%	-46.83%	-27.21%		0.18
TNGXTango Therapeutics, Inc.	1.41B	10.44	-8.77	15.17%	-151.15%	-62.81%		0.18

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-
Cost of Goods Sold+	0	86K	776K	979K	1.07M	1.1M
COGS % of Revenue	-	-	-	-	-	-
Gross Profit+	0	-86K	-776K	-979K	-1.07M	-1.1M
Gross Margin %	-	-	-	-	-	-
Gross Profit Growth %	-	-	-8.02%	-0.26%	-0.1%	-0.03%
Operating Expenses+	8.01M	9.24M	13.79M	32.14M	34.61M	34.94M
OpEx % of Revenue	-	-	-	-	-	-
Selling, General & Admin	1.37M	1.7M	2.34M	11.25M	9.26M	7.92M
SG&A % of Revenue	-	-	-	-	-	-
Research & Development	6.64M	7.54M	11.45M	20.89M	26.42M	27.02M
R&D % of Revenue	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	-1.07M	0
Operating Income+	-8.01M	-9.24M	-13.79M	-32.14M	35.68M	-36.04M
Operating Margin %	-	-	-	-	-	-
Operating Income Growth %	-	-0.15%	-0.49%	-1.33%	2.11%	-2.01%
EBITDA+	-7.94M	-9.16M	-13.01M	-31.16M	36.75M	-34.94M
EBITDA Margin %	-	-	-	-	-	-
EBITDA Growth %	-	-0.15%	-0.42%	-1.39%	2.18%	-1.95%
D&A (Non-Cash Add-back)	66K	86K	776K	979K	1.07M	1.1M
EBIT	-8.01M	-9.24M	-13.99M	-33.72M	-29.1M	-31.4M
Net Interest Income+	776K	396K	-13.06M	21K	4.72M	3.93M
Interest Income	776K	613K	211K	1.79M	4.75M	4.28M
Interest Expense	0	217K	13.27M	1.77M	39K	344K
Other Income/Expense	-308K	520K	-13.47M	-1.61M	6.54M	4.3M
Pretax Income+	-8.32M	-8.72M	-27.26M	-33.74M	-29.14M	-31.74M
Pretax Margin %	-	-	-	-	-	-
Income Tax+	146K	158K	7K	20K	16K	6K
Effective Tax Rate %	1.02%	1.02%	1%	1%	1%	1%
Net Income+	-8.46M	-8.88M	-27.27M	-33.76M	-29.16M	-31.75M
Net Margin %	-	-	-	-	-	-
Net Income Growth %	-	-0.05%	-2.07%	-0.24%	0.14%	-0.09%
Net Income (Continuing)	-8.46M	-8.88M	-27.27M	-33.76M	-29.16M	-31.75M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0
EPS (Diluted)+	-0.13	-0.22	-0.67	-0.53	-0.42	-0.45
EPS Growth %	-	-0.69%	-2.05%	0.21%	0.21%	-0.07%
EPS (Basic)	-0.13	-0.22	-0.67	-0.53	-0.42	-0.45
Diluted Shares Outstanding	67.62M	40.43M	40.53M	63.53M	69.38M	69.93M
Basic Shares Outstanding	67.62M	40.43M	40.53M	63.53M	69.38M	69.93M
Dividend Payout Ratio	-	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	29.83M	47.45M	32.64M	106.48M	85.76M	64.23M
Cash & Short-Term Investments	28.13M	46.02M	31.32M	104.53M	81.79M	59.6M
Cash Only	1.83M	15.6M	23.24M	5.84M	12.66M	13.72M
Short-Term Investments	26.3M	30.42M	8.08M	98.69M	69.13M	45.88M
Accounts Receivable	141K	477K	480K	32K	19K	332K
Days Sales Outstanding	-	-	-	-	-	-
Inventory	1.13M	0	-8.17M	0	-19K	0
Days Inventory Outstanding	-	-	-	-	-	-
Other Current Assets	-187.3K	576K	8.79M	1.13M	3.5M	3.25M
Total Non-Current Assets+	1.73M	5.53M	9.57M	13.67M	21.63M	21.98M
Property, Plant & Equipment	1.71M	5.39M	7.55M	13.28M	21.16M	21.54M
Fixed Asset Turnover	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0
Other Non-Current Assets	16K	139K	2.03M	391K	471K	432K
Total Assets+	31.56M	52.99M	42.22M	120.15M	107.39M	86.2M
Asset Turnover	-	-	-	-	-	-
Asset Growth %	-	0.68%	-0.2%	1.85%	-0.11%	-0.2%
Total Current Liabilities+	1.35M	2.09M	4.41M	4.34M	7.1M	8.68M
Accounts Payable	893K	964K	1.2M	1.42M	2.57M	3.53M
Days Payables Outstanding	-	4.09K	565.84	530.54	872.06	1.17K
Short-Term Debt	0	0	0	0	1.06M	1.01M
Deferred Revenue (Current)	0	0	0	0	0	0
Other Current Liabilities	0	599K	2.41M	1.34M	-983K	389K
Current Ratio	22.11x	22.73x	7.41x	24.55x	12.07x	7.40x
Quick Ratio	21.27x	22.73x	9.26x	24.55x	12.08x	7.40x
Cash Conversion Cycle	-	-	-	-	-	-
Total Non-Current Liabilities+	30.4M	59.33M	72.59M	10.15M	15.81M	14.86M
Long-Term Debt	0	53.96M	53.96M	0	5.61M	5.56M
Capital Lease Obligations	0	0	0	4.52M	6.6M	5.96M
Deferred Tax Liabilities	0	0	0	0	0	0
Other Non-Current Liabilities	30.4M	5.37M	18.62M	5.63M	3.6M	3.34M
Total Liabilities	31.75M	61.42M	76.99M	14.49M	22.91M	23.54M
Total Debt+	0	53.96M	53.96M	5.19M	13.28M	12.54M
Net Debt	-1.83M	38.37M	30.73M	-643K	619K	-1.19M
Debt / Equity	-	-	-	0.05x	0.16x	0.20x
Debt / EBITDA	-	-	-	-	0.36x	-
Net Debt / EBITDA	-	-	-	-	0.02x	-
Interest Coverage	-	-42.60x	-1.04x	-18.17x	914.87x	-104.77x
Total Equity+	-193K	-8.43M	-34.78M	105.66M	84.47M	62.67M
Equity Growth %	-	-42.67%	-3.13%	4.04%	-0.2%	-0.26%
Book Value per Share	-0.00	-0.21	-0.86	1.66	1.22	0.90
Total Shareholders' Equity	-193K	-8.43M	-34.78M	105.66M	84.47M	62.67M
Common Stock	0	690	0	0	0	0
Retained Earnings	-16.69M	-25.57M	-52.84M	-86.6M	-115.76M	-147.51M
Treasury Stock	0	0	0	0	0	0
Accumulated OCI	-21K	-60.02K	0	0	0	0
Minority Interest	0	0	0	0	0	0

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-6.91M	-7.25M	-11.81M	-23.88M	-17.96M	-19.78M
Operating CF Margin %	-	-	-	-	-	-
Operating CF Growth %	-	-0.05%	-0.63%	-1.02%	0.25%	-0.1%
Net Income	-8.46M	-8.88M	-27.27M	-33.76M	-29.16M	-31.75M
Depreciation & Amortization	66K	86K	776K	979K	1.07M	1.1M
Stock-Based Compensation	546K	0	0	0	0	0
Deferred Taxes	994K	0	0	0	0	0
Other Non-Cash Items	12K	646K	14.1M	9.21M	7.63M	9.7M
Working Capital Changes	-64K	899K	585K	-307K	2.49M	1.17M
Change in Receivables	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0
Change in Payables	148K	114K	239K	220K	1.14M	965K
Cash from Investing+	-10.16M	-7.82M	19.27M	-89.94M	18.68M	20.77M
Capital Expenditures	-1.29M	-3.77M	-2.93M	-904K	-6.4M	-2.24M
CapEx % of Revenue	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	-8.87K	-4.05M	22.2M	-89.03M	25.08M	-103K
Cash from Financing+	5.32M	29.32M	111K	96.91M	5.3M	25K
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	73K	0	0	93.54M	5.25M	0
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	-8.2M	-11.02M	-14.74M	-24.78M	-24.36M	-22.02M
FCF Margin %	-	-	-	-	-	-
FCF Growth %	-	-0.34%	-0.34%	-0.68%	0.02%	0.1%
FCF per Share	-0.12	-0.27	-0.36	-0.39	-0.35	-0.31
FCF Conversion (FCF/Net Income)	0.82x	0.82x	0.43x	0.71x	0.62x	0.62x
Interest Paid	0	0	0	0	52K	321K
Taxes Paid	0	0	0	0	0	0

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-	-95.27%	-30.67%	-43.16%
Return on Invested Capital (ROIC)	-	-49.68%	-79.9%	-47.74%	28.15%	-36.88%
Debt / Equity	-	-	-	0.05x	0.16x	0.20x
Interest Coverage	-	-42.60x	-1.04x	-18.17x	914.87x	-104.77x
FCF Conversion	0.82x	0.82x	0.43x	0.71x	0.62x	0.62x

Frequently Asked Questions

Growth & Financials

Alpha Tau Medical Ltd. (DRTS) grew revenue by 0.0% over the past year. Growth has been modest.

Alpha Tau Medical Ltd. (DRTS) reported a net loss of $40.0M for fiscal year 2024.

Dividend & Returns

Alpha Tau Medical Ltd. (DRTS) has a return on equity (ROE) of -43.2%. Negative ROE indicates the company is unprofitable.

Alpha Tau Medical Ltd. (DRTS) had negative free cash flow of $22.0M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener